Synopsis
0
JDMF
0
EU WC
0
VMF
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Anhydrous, Atropine Sulfate
2. Atropen
3. Atropin Augenl
4. Atropine Sulfate
5. Atropine Sulfate Anhydrous
6. Atropinol
7. Augenl, Atropin
8. Sulfate Anhydrous, Atropine
9. Sulfate, Atropine
1. Dl-hyoscyamine
2. Tropine Tropate
3. Atropen
4. Atropin
5. 51-55-8
6. Dl-tropyltropate
7. Atropinol
8. Eyesules
9. Isopto-atropine
10. Troyl Tropate
11. Hyoscyamine
12. Atropina
13. Atropin-flexiolen
14. (+,-)-tropyl Tropate
15. Atropin [german]
16. Atropina [italian]
17. (+-)-hyoscyamine
18. Tropine, Tropate (ester)
19. (+-)-atropine
20. Tropic Acid, Ester With Tropine
21. (+/-)-atropine
22. (+/-)-hyoscyamine
23. Ccris 3080
24. Atropine (usp)
25. Tropic Acid, 3-alpha-tropanyl Ester
26. Atropinum
27. Hsdb 2199
28. Dl-tropanyl 2-hydroxy-1-phenylpropionate
29. 2-phenylhydracrylic Acid 3-alpha-tropanyl Ester
30. (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl Tropate
31. Ai3-60219
32. Beta-phenyl-gamma-oxypropionsaure-tropyl-ester [german]
33. Dl-tropyl Tropate
34. (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate
35. 1alphah,5alphah-tropan-3alpha-ol (+-)-tropate (ester)
36. Beta-phenyl-gamma-oxypropionsaeure-tropyl-ester [german]
37. Tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate
38. 8-methyl-8-azabicyclo[3.2.1]oct-3-yl Tropate
39. Mls000069795
40. Chebi:16684
41. 7c0697dr9i
42. 8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate
43. [(1s,5r)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl] 3-hydroxy-2-phenyl-propanoate
44. Alpha-(hydroxymethyl)benzeneacetic Acid 8-methyl-8-azabicyclo(3.2.1)oct-3-yl Ester
45. Endo-(+/-)-alpha-(hydroxymethyl)benzeneacetic Acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl Ester
46. Benzeneacetic Acid, Alpha-(hydroxymethyl)-8-methyl-8-azabicyclo(3,2,1)oct-3-yl Ester, Endo-(+-)-
47. Ncgc00017333-03
48. Smr000058248
49. Dsstox_cid_113
50. Ab00694549-11
51. Dsstox_rid_75375
52. Dsstox_gsid_20113
53. Benzeneacetic Acid, Alpha-(hydroxymethyl)-, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl Ester, Endo-(+-)-
54. Cas-51-55-8
55. Atropen (tn)
56. Protamine & Atropine
57. Atropine [usp:ban]
58. Einecs 200-104-8
59. Tropine (+/-)-tropate
60. Ropine Tropate
61. Unii-7c0697dr9i
62. (3-endo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl Tropate
63. Atropine Solution
64. (1r,3r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate
65. Ncgc00159345-02
66. 3-tropoyloxytropane
67. 1-alpha-h,5-alpha-h-tropan-3-alpha-ol (+-)-tropate (ester)
68. Atropine [mi]
69. Atropine [vandf]
70. Atropinum [hpus]
71. Opera_id_1088
72. Atropine [mart.]
73. Beta-phenyl-gamma-oxypropionsaure-tropyl-ester
74. Atropine [usp-rs]
75. Atropine [who-dd]
76. Bmse000649
77. Beta-phenyl-gamma-oxypropionsaeure-tropyl-ester
78. Schembl2812
79. [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
80. Atropine, Analytical Standard
81. Gtpl320
82. Benzeneacetic Acid, Alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl Ester
83. Mls001148094
84. Mls002695888
85. Atropine [green Book]
86. Atnaa Component Atropine
87. Atropine [ep Impurity]
88. Atropine [orange Book]
89. Chembl254656
90. Chembl475124
91. Chembl517712
92. Cid_174174
93. Megxp0_001878
94. Atropine [ep Monograph]
95. Atropine ((+/-))
96. Atropine [usp Monograph]
97. Atropine, (+/-)-
98. Dtxsid4020113
99. Acon1_000046
100. Chebi:78734
101. Duodote Component Atropine
102. Atropine, >=95.0% (nt)
103. Atropine Component Of Atnaa
104. Bdbm200229
105. Dtxsid601141720
106. Hms2089a16
107. Hms2231g17
108. Hms3259m13
109. Bcp15060
110. Hy-b1205
111. Atropine Component Of Duodote
112. Atropine, >=99% (tlc), Powder
113. Tox21_110816
114. Tox21_111590
115. Tox21_200487
116. 1-alpha-h,5-alpha-h-tropan-3-alpha-ol (+-)-tropate (ester) (8ci)
117. Bdbm50403547
118. S4713
119. Akos015955538
120. Cs-4834
121. Db00572
122. Nc00493
123. Ncgc00017333-02
124. Ncgc00017333-04
125. Ncgc00017333-05
126. Ncgc00017333-06
127. Ncgc00142514-01
128. Ncgc00142514-03
129. Ncgc00258041-01
130. Ncgc00385525-01
131. As-56020
132. Benzeneacetic Acid, Alpha-(hydroxymethyl)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl Ester, Endo-(+-)-
133. Atropine, Meets Usp Testing Specifications
134. C1504
135. Ft-0627165
136. C01479
137. D00113
138. Q26272
139. Ab00694549-12
140. Ab00694549_14
141. Rac-tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate
142. Brd-a27290375-001-01-8
143. Brd-a27290375-330-01-1
144. Atropine, European Pharmacopoeia (ep) Reference Standard
145. Homatropine Hydrobromide Impurity D [ep Impurity]
146. 1.alpha.h,5.alpha.h-tropan-3.alpha.-ol (+/-)-tropate (ester)
147. (3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl Alpha-(hydroxymethyl)benzeneacetate
148. [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenyl-propanoate
149. [(1s,5r)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenyl-propanoate
150. Alpha-hydroxymethylphenylacetic Acid (1r,5s)-8-methyl-8-azabicyclo[3.2.1]octane-3-yl Ester
151. Atropine For Peak Identification, European Pharmacopoeia (ep) Reference Standard
152. Rac-(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate
153. (1beta,3alpha,5beta)-3-[(3-hydroxy-1-oxo-2-phenylpropyl)oxy]-8-methyl-8-azabicyclo[3.2.1]octane
154. 16175-85-2
155. Benzeneacetic Acid, .alpha.-(hydroxymethyl)-(3-endo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl Ester
156. Benzeneacetic Acid, .alpha.-(hydroxymethyl)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl Ester, Endo-(+/-)-
157. Benzeneacetic Acid, Alpha-(hydroxymethyl)- (3-endo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl Ester
158. Benzeneacetic Acid, Alpha-(hydroxymethyl)-, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl Ester, Endo-(+/-)-
| Molecular Weight | 289.4 g/mol |
|---|---|
| Molecular Formula | C17H23NO3 |
| XLogP3 | 1.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 5 |
| Exact Mass | 289.16779360 g/mol |
| Monoisotopic Mass | 289.16779360 g/mol |
| Topological Polar Surface Area | 49.8 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 353 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Atropen |
| PubMed Health | Atropine (Injection) |
| Drug Classes | Anesthetic Adjunct, Cholinergic Antagonist, Gastrointestinal Agent, Nerve Gas Antidote, Urinary Antispasmodic |
| Drug Label | Each prefilled auto-injector provides a dose of the antidote atropine in a self-contained unit, specially designed for self or caregiver administration. Four strengths of AtroPen are available; they are AtroPen 0.25 mg, AtroPen 0.5 mg, AtroPen... |
| Active Ingredient | Atropine |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 0.25mg sulfate/0.3ml; eq 1mg sulfate/0.7ml; eq 0.5mg sulfate/0.7ml; eq 2mg sulfate/0.7ml |
| Market Status | Prescription |
| Company | Meridian Medcl |
| 2 of 2 | |
|---|---|
| Drug Name | Atropen |
| PubMed Health | Atropine (Injection) |
| Drug Classes | Anesthetic Adjunct, Cholinergic Antagonist, Gastrointestinal Agent, Nerve Gas Antidote, Urinary Antispasmodic |
| Drug Label | Each prefilled auto-injector provides a dose of the antidote atropine in a self-contained unit, specially designed for self or caregiver administration. Four strengths of AtroPen are available; they are AtroPen 0.25 mg, AtroPen 0.5 mg, AtroPen... |
| Active Ingredient | Atropine |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 0.25mg sulfate/0.3ml; eq 1mg sulfate/0.7ml; eq 0.5mg sulfate/0.7ml; eq 2mg sulfate/0.7ml |
| Market Status | Prescription |
| Company | Meridian Medcl |
Adjuvants, Anesthesia; Anti-Arrhythmia Agents; Antidotes; Bronchodilator Agents; Muscarinic Antagonists; Mydriatics; Parasympatholytics
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
... people poisoned by anticholinesterase organic phosphorus compounds have an increased tolerance for atropine sulfate.
Hayes, W.J., Jr., E.R. Laws, Jr., (eds.). Handbook of Pesticide Toxicology. Volume 2. Classes of Pesticides. New York, NY: Academic Press, Inc., 1991., p. 951
MEDICATION (VET): ...USED ROUTINELY AS ADJUNCT TO GENERAL ANESTHESIA...TO DECR SALIVARY & AIRWAY SECRETIONS. ... USED TO FACILITATE OPHTHALMOSCOPIC EXAM OF INTERNAL OCULAR STRUCTURES & FUNCTIONS &...FOR TREATMENT OF VARIOUS OCULAR DISORDERS. ... ATROPINE IS ESSENTIAL ANTIDOTE TO ANTICHOLINESTERASE OVERDOSAGE & POISONING.
Jones, L.M., et al. Veterinary Pharmacology & Therapeutics. 4th ed. Ames: Iowa State University Press, 1977., p. 159
Adequate doses of atropine can abolish many types of reflex vagal cardiac slowing or asystole--for example, from inhalation of irritant vapors, stimulation of the carotid sinus, pressure on the eyeballs, peritoneal stimulation, or injection of contrast dye during cardiac catheterization. It also prevents or abruptly abolishes bradycardia or asystole caused by choline esters, acetylcholinesterase inhibitors, or other parasympathomimetic drugs, as well as cardiac arrest from electrical stimulation of the vagus.
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 165
For more Therapeutic Uses (Complete) data for ATROPINE (24 total), please visit the HSDB record page.
FATALITIES FROM ATROPINE...ARE RARE, BUT SOMETIMES OCCUR IN CHILDREN. OF ALL POTENT ALKALOIDS, ATROPINE HAS ONE OF WIDEST MARGINS OF SAFETY. FATAL DOSE... NOT KNOWN; 200-MG DOSE..USED THERAPEUTICALLY FOR MENTAL ILLNESS, &...1000 MG HAVE BEEN SURVIVED. IN CHILDREN, 10 MG OR LESS MAY BE LETHAL.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 522
DRY MOUTH, BLURRED VISION, PHOTOPHOBIA, ANHIDROSIS, & CONSTIPATION ARE UNAVOIDABLE SIDE EFFECTS...
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 840
...CONTRAINDICATED IN PERSONS WHOSE INTRAOCULAR PRESSURE IS...ELEVATED...IN PRESENCE OF PROSTATIC HYPERTROPHY OR ORGANIC PYLORIC STENOSIS. ...USED CAUTIOUSLY IN PT WITH PROSTATISM, URINARY RETENTION, DIABETES, HYPERTHYROIDISM, TACHYCARDIA, IN ELDERLY PERSONS, & CHILDREN UNDER 6 YR OF AGE.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 840
ATROPINE IS OF NO VALUE IN DELAYED TYPE OF MUSHROOM POISONING DUE TO TOXINS OF A PHALLOIDES & CERTAIN OTHER SPECIES OF SAME GENUS.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 531
For more Drug Warnings (Complete) data for ATROPINE (16 total), please visit the HSDB record page.
For the treatment of poisoning by susceptible organophosphorous nerve agents having anti-cholinesterase activity (cholinesterase inhibitors) as well as organophosphorous or carbamate insecticides.
FDA Label
Atropine, a naturally occurring belladonna alkaloid, is a racemic mixture of equal parts of d- and l-hyoscyamine, whose activity is due almost entirely to the levo isomer of the drug. Atropine is commonly classified as an anticholinergic or antiparasympathetic (parasympatholytic) drug. More precisely, however, it is termed an antimuscarinic agent since it antagonizes the muscarine-like actions of acetylcholine and other choline esters. Adequate doses of atropine abolish various types of reflex vagal cardiac slowing or asystole. The drug also prevents or abolishes bradycardia or asystole produced by injection of choline esters, anticholinesterase agents or other parasympathomimetic drugs, and cardiac arrest produced by stimulation of the vagus. Atropine may also lessen the degree of partial heart block when vagal activity is an etiologic factor. Atropine in clinical doses counteracts the peripheral dilatation and abrupt decrease in blood pressure produced by choline esters. However, when given by itself, atropine does not exert a striking or uniform effect on blood vessels or blood pressure.
Adjuvants, Anesthesia
Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Bronchodilator Agents
Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)
Mydriatics
Agents that dilate the pupil. They may be either sympathomimetics or parasympatholytics. (See all compounds classified as Mydriatics.)
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)
A03BA01
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
A - Alimentary tract and metabolism
A03 - Drugs for functional gastrointestinal disorders
A03B - Belladonna and derivatives, plain
A03BA - Belladonna alkaloids, tertiary amines
A03BA01 - Atropine
A - Alimentary tract and metabolism
A03 - Drugs for functional gastrointestinal disorders
A03B - Belladonna and derivatives, plain
A03BA - Belladonna alkaloids, tertiary amines
A03BA03 - Hyoscyamine
S - Sensory organs
S01 - Ophthalmologicals
S01F - Mydriatics and cycloplegics
S01FA - Anticholinergics
S01FA01 - Atropine
Absorption
Atropine is rapidly and well absorbed after intramuscular administration. Atropine disappears rapidly from the blood and is distributed throughout the various body tissues and fluids.
Route of Elimination
Much of the drug is destroyed by enzymatic hydrolysis, particularly in the liver; from 13 to 50% is excreted unchanged in the urine.
BELLADONNA ALKALOIDS...ARE ABSORBED RAPIDLY FROM THE GI TRACT. THEY ALSO ENTER CIRCULATION WHEN APPLIED...TO MUCOSAL SURFACES OF THE BODY. ABSORPTION FROM INTACT SKIN IS LIMITED, ALTHOUGH EFFICIENT ABSORPTION DOES OCCUR IN THE POSTAURICULAR REGION. ... ATROPINE HAS A HALF-LIFE OF APPROX 4 HR; HEPATIC METAB ACCOUNTS FOR THE ELIMINATION OF ABOUT HALF OF A DOSE, & THE REMAINDER IS EXCRETED UNCHANGED IN THE URINE.
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 167
...WHEN ADMIN TO MOTHER PASS RAPIDLY INTO FETAL BLOOD.
The Chemical Society. Foreign Compound Metabolism in Mammals Volume 3. London: The Chemical Society, 1975., p. 634
IN DOG, 27% OF SC DOSE OF (3)H-ATROPINE WAS EXCRETED IN 2-HR URINE MOSTLY UNCHANGED. 50%...WAS EXCRETED WITHIN 6-HR, & RENAL EXCRETION OF ATROPINE OCCURRED BY GLOMERULAR FILTRATION & TUBULAR SECRETION.
The Chemical Society. Foreign Compound Metabolism in Mammals. Volume 1: A Review of the Literature Published Between 1960 and 1969. London: The Chemical Society, 1970., p. 69
AFTER IM ADMIN OF RADIOACTIVELY LABELED ATROPINE TO MAN, DISAPPEARANCE OF RADIOACTIVITY FROM PLASMA WAS BIPHASIC, WITH...HALF-LIVES OF 2 HR & 13-28 HR... BETWEEN 77 & 94% OF TOTAL RADIOACTIVITY WAS EXCRETED IN URINE... CHROMATOGRAPHIC EVIDENCE SUGGESTED THAT RELATIVE PROPORTIONS OF METABOLITIES VARIED WITH TIME.
The Chemical Society. Foreign Compound Metabolism in Mammals. Volume 2: A Review of the Literature Published Between 1970 and 1971. London: The Chemical Society, 1972., p. 455
For more Absorption, Distribution and Excretion (Complete) data for ATROPINE (6 total), please visit the HSDB record page.
Much of the drug is destroyed by enzymatic hydrolysis, particularly in the liver. From 13 to 50% is excreted unchanged in the urine.
... HEPATIC METAB ACCOUNTS FOR THE ELIMINATION OF ABOUT HALF OF A DOSE, & THE REMAINDER IS EXCRETED UNCHANGED IN THE URINE.
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 167
WITH (14)C RESTRICTED TO ALPHA-CARBON...ON TROPIC ACID PORTION...10 RADIOACTIVE...PRODUCTS...IN MOUSE & RAT URINE, PRINCIPAL METABOLITES WERE GLUCURONIDE CONJUGATES OF HYDROXYATROPINES FORMED IN VIVO BY METABOLIC HYDROXYLATION OF AROMATIC RING...GLUCURONIDES OF ATROPINE COULD NOT BE DETECTED IN HUMAN URINE...
Gosselin, R.E., H.C. Hodge, R.P. Smith, and M.N. Gleason. Clinical Toxicology of Commercial Products. 4th ed. Baltimore: Williams and Wilkins, 1976., p. III-44
3.0 ± 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.
AFTER IM ADMIN OF RADIOACTIVELY LABELED ATROPINE TO MAN, DISAPPEARANCE OF RADIOACTIVITY FROM PLASMA WAS BIPHASIC, WITH...HALF-LIVES OF 2 HR & 13-28 HR...
The Chemical Society. Foreign Compound Metabolism in Mammals. Volume 2: A Review of the Literature Published Between 1970 and 1971. London: The Chemical Society, 1972., p. 455
Atropine binds to and inhibit muscarinic acetylcholine receptors, producing a wide range of anticholinergic effects.
Atropine... competes with ACh & other muscarinic agonists for a common binding site on the muscarinic receptor. The binding site for competitive antagonists & acetylcholine is in a cleft predicted to be formed by several of the receptor's 7 transmembrane helices, as shown recently for the position of retinol in the mammalian rhodopsin structure. An aspartic acid present in the N-terminal portion of the third transmembrane helix of all 5 muscarinic receptor subtypes is believed to form an ionic bond with the cationic quaternary nitrogen in acetylcholine & the tertiary or quaternary nitrogen of the antagonists.
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 164
ATROPINE...(IS A) SELECTIVE ANTAGONIST OF MUSCARINIC AGENTS AT CORRESPONDING RECEPTORS OF SMOOTH & CARDIAC MUSCLE & EXOCRINE GLAND CELLS. THIS ANTAGONISM IS SO SELECTIVE THAT ATROPINE BLOCKADE OF ACTIONS OF NONCHOLINOMIMETIC DRUG... TAKEN AS EVIDENCE THAT DRUG ACTS INDIRECTLY THROUGH ACH RELEASE OR SOME OTHER CHOLINERGIC MECHANISM.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 516
...The site of action of atropine, a non-selective muscarinic receptor antagonist, in reducing increased muscle rigidity ...induced by the selective dopamine D2 receptor antagonist, raclopride /was investigated/. Atropine significantly reduced raclopride-induced EMG increases in rat hindlimb muscles, when injected into the ventral striatum, but not the dorsal striatum or the substantia nigra. Atropine's site of action was localized to a small area of muscarinic receptors within the ventral part of the striatum... These findings provide new information about the regulation of motor control by muscarinic receptor antagonists & additional evidence about the functional heterogeneity of the striatum.
PMID:11779574 Hemsley KM, Crocker AD; Eur J Pharmacol 434(3): 117-123 (2002)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7334
Submission : 1988-02-09
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5791
Submission : 1985-03-27
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35769
Submission : 2021-05-06
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-12-23
Pay. Date : 2015-09-22
DMF Number : 29521
Submission : 2015-09-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5514
Submission : 1983-07-06
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
A drug-device combination of low-dose atropine in the Company’s Optejet dispensing platform is being investigated as a potential treatment for pediatric progressive myopia.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Brand Name: Optejet
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2024
Lead Product(s) : Atropine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Eyenovia Provides Update On Phase 3 CHAPERONE Study
Details : A drug-device combination of low-dose atropine in the Company’s Optejet dispensing platform is being investigated as a potential treatment for pediatric progressive myopia.
Brand Name : Optejet
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 15, 2024
Details:
Eyenovia re-acquired rights to MicroPine in the U.S. and Canada, expanding its phase III pipeline, being evaluated as a potential treatment for pediatric progressive myopia.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Brand Name: MicroPine
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Eyenovia
Deal Size: Undisclosed Upfront Cash: $5.0 million
Deal Type: Acquisition January 16, 2024
Lead Product(s) : Atropine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Eyenovia
Deal Size : Undisclosed
Deal Type : Acquisition
Eyenovia Re-Acquires Development Rights To Micropine in U.S. and Canada
Details : Eyenovia re-acquired rights to MicroPine in the U.S. and Canada, expanding its phase III pipeline, being evaluated as a potential treatment for pediatric progressive myopia.
Brand Name : MicroPine
Molecule Type : Small molecule
Upfront Cash : $5.0 million
January 16, 2024
Details:
Under the agreement, Meridian will supply DuoDote to the Administration for Strategic Preparedness and Response within the United States. DuoDote® is an FDA-approved dual-chamber autoinjector (atropine and pralidoxime chloride) chemical nerve agent antidote.
Lead Product(s): Atropine,Pralidoxime Chloride
Therapeutic Area: Pharmacology/Toxicology Brand Name: DuoDote
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: ASPR
Deal Size: $9.9 million Upfront Cash: Undisclosed
Deal Type: Agreement November 14, 2023
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : ASPR
Deal Size : $9.9 million
Deal Type : Agreement
Meridian Medical Technologies, Kindeva Drug Delivery’s Global Health Security Division, Awarded ...
Details : Under the agreement, Meridian will supply DuoDote to the Administration for Strategic Preparedness and Response within the United States. DuoDote® is an FDA-approved dual-chamber autoinjector (atropine and pralidoxime chloride) chemical nerve agent anti...
Brand Name : DuoDote
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 14, 2023
Details:
NVK002 (atropine) inhibits the muscarinic actions of acetylcholine, which is investigated for anti-allergy and dry eye syndrome and progressive myopia.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Brand Name: NVK002
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Lead Product(s) : Atropine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NVK002 (atropine) inhibits the muscarinic actions of acetylcholine, which is investigated for anti-allergy and dry eye syndrome and progressive myopia.
Brand Name : NVK002
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 11, 2023
Details:
NVK002 (atropine) is an investigational, preservative-free, low-dose atropine eye drop, using Vyluma’s proprietary technology to address stability, tolerability, and safety and developed for the treatment of Pediatric Myopia.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Brand Name: NVK002
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Nevakar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Lead Product(s) : Atropine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Nevakar
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NVK002 (atropine) is an investigational, preservative-free, low-dose atropine eye drop, using Vyluma’s proprietary technology to address stability, tolerability, and safety and developed for the treatment of Pediatric Myopia.
Brand Name : NVK002
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 06, 2023
Details:
NVK002 (atropine) is a proprietary, investigational, low-dose, preservative-free atropine eye drop administered nightly as a potential treatment for the progression of myopia in children.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Brand Name: NVK-002
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Laboratoires Thea
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Lead Product(s) : Atropine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Laboratoires Thea
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NVK002 (atropine) is a proprietary, investigational, low-dose, preservative-free atropine eye drop administered nightly as a potential treatment for the progression of myopia in children.
Brand Name : NVK-002
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 27, 2022
Details:
NVK002 (atropine) is a proprietary, investigational, preservative-free eye drop administered nightly, which, if approved, would be the first-in-class pharmaceutical treatment for myopia progression in children.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Brand Name: NVK002
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Nevakar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Lead Product(s) : Atropine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Nevakar
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NVK002 (atropine) is a proprietary, investigational, preservative-free eye drop administered nightly, which, if approved, would be the first-in-class pharmaceutical treatment for myopia progression in children.
Brand Name : NVK002
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 01, 2022
Details:
The agreement represents an expansion of the previously announced exclusive licensing agreement for the commercialization of NVK002 (having Atropine) in Europe and other select countries.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Brand Name: NVK002
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Laboratoires Thea
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 14, 2022
Lead Product(s) : Atropine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Laboratoires Thea
Deal Size : $150.0 million
Deal Type : Licensing Agreement
Details : The agreement represents an expansion of the previously announced exclusive licensing agreement for the commercialization of NVK002 (having Atropine) in Europe and other select countries.
Brand Name : NVK002
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 14, 2022
Details:
The financing will support the Phase III clinical study for NVK002, Vyluma’s first-in-class pharmaceutical treatment for slowing the progression of myopia in children.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Brand Name: NVK002
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Oxford Finance LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 09, 2022
Lead Product(s) : Atropine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Oxford Finance LLC
Deal Size : Undisclosed
Deal Type : Financing
Details : The financing will support the Phase III clinical study for NVK002, Vyluma’s first-in-class pharmaceutical treatment for slowing the progression of myopia in children.
Brand Name : NVK002
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 09, 2022
Details:
The acquisition marks Hikma’s expansion into Canada and a portfolio of 25 sterile injectable products including the marketed product Atropine-G, three in-licenced ophthalmic products and a pipeline of seven additional products, four of which are approved by Health Canada.
Lead Product(s): Atropine
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Atropine-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Hikma Pharmaceuticals
Deal Size: $45.8 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 17, 2022
Lead Product(s) : Atropine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Hikma Pharmaceuticals
Deal Size : $45.8 million
Deal Type : Acquisition
Hikma Expands Into Canada with Acquisition of Teligent Sterile Injectable Assets
Details : The acquisition marks Hikma’s expansion into Canada and a portfolio of 25 sterile injectable products including the marketed product Atropine-G, three in-licenced ophthalmic products and a pipeline of seven additional products, four of which are approv...
Brand Name : Atropine-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
RLD : No
TE Code :
Brand Name : ATROPINE
Dosage Form : SOLUTION;INTRAMUSCULAR
Dosage Strength : EQ 2MG SULFATE/0.7ML
Approval Date : 1987-01-30
Application Number : 71295
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : Yes
TE Code :
Brand Name : ATROPEN
Dosage Form : SOLUTION;INTRAMUSCULAR
Dosage Strength : EQ 2MG SULFATE/0.7ML
Approval Date : 1982-01-01
Application Number : 17106
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : ATROPEN
Dosage Form : SOLUTION;INTRAMUSCULAR
Dosage Strength : EQ 1MG SULFATE/0.7ML
Approval Date : 2003-06-19
Application Number : 17106
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : ATROPEN
Dosage Form : SOLUTION;INTRAMUSCULAR
Dosage Strength : EQ 0.5MG SULFATE/0.7ML
Approval Date : 2003-06-19
Application Number : 17106
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : ATROPEN
Dosage Form : SOLUTION;INTRAMUSCULAR
Dosage Strength : EQ 0.25MG SULFATE/0.3ML
Approval Date : 2004-09-17
Application Number : 17106
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
ATROPINE; PRALIDOXIME CHLORIDE
Brand Name : DUODOTE
Dosage Form : INJECTABLE;INTRAMUSCULAR
Dosage Strength : 2.1MG/0.7ML;600MG/2ML
Approval Date : 2006-09-28
Application Number : 21983
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : No
TE Code :
Brand Name : ATROPINE (AUTOINJECTOR)
Dosage Form : SOLUTION;INTRAMUSCULAR
Dosage Strength : EQ 2MG SULFATE/0.7ML (EQ 2MG SULFATE/0.7ML)
Approval Date : 2018-07-09
Application Number : 212319
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
ATROPINE; PRALIDOXIME CHLORIDE
Brand Name : ATNAA
Dosage Form : INJECTABLE;INTRAMUSCULAR
Dosage Strength : 2.1MG/0.7ML;600MG/2ML
Approval Date : 2002-01-17
Application Number : 21175
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Direct Compression
Co-Processed Excipients
Granulation
Lubricants & Glidants
Coating Systems & Additives
Thickeners and Stabilizers
Parenteral
Taste Masking
API Stability Enhancers
Emulsifying Agents
Controlled & Modified Release
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
Analytical Methods
ABOUT THIS PAGE
A Atropine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Atropine, including repackagers and relabelers. The FDA regulates Atropine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Atropine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Atropine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Atropine supplier is an individual or a company that provides Atropine active pharmaceutical ingredient (API) or Atropine finished formulations upon request. The Atropine suppliers may include Atropine API manufacturers, exporters, distributors and traders.
click here to find a list of Atropine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Atropine DMF (Drug Master File) is a document detailing the whole manufacturing process of Atropine active pharmaceutical ingredient (API) in detail. Different forms of Atropine DMFs exist exist since differing nations have different regulations, such as Atropine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Atropine DMF submitted to regulatory agencies in the US is known as a USDMF. Atropine USDMF includes data on Atropine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Atropine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Atropine suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Atropine Drug Master File in Korea (Atropine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Atropine. The MFDS reviews the Atropine KDMF as part of the drug registration process and uses the information provided in the Atropine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Atropine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Atropine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Atropine suppliers with KDMF on PharmaCompass.
A Atropine CEP of the European Pharmacopoeia monograph is often referred to as a Atropine Certificate of Suitability (COS). The purpose of a Atropine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Atropine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Atropine to their clients by showing that a Atropine CEP has been issued for it. The manufacturer submits a Atropine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Atropine CEP holder for the record. Additionally, the data presented in the Atropine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Atropine DMF.
A Atropine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Atropine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Atropine suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Atropine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Atropine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Atropine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Atropine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Atropine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Atropine suppliers with NDC on PharmaCompass.
Atropine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Atropine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Atropine GMP manufacturer or Atropine GMP API supplier for your needs.
A Atropine CoA (Certificate of Analysis) is a formal document that attests to Atropine's compliance with Atropine specifications and serves as a tool for batch-level quality control.
Atropine CoA mostly includes findings from lab analyses of a specific batch. For each Atropine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Atropine may be tested according to a variety of international standards, such as European Pharmacopoeia (Atropine EP), Atropine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Atropine USP).
LOOKING FOR A SUPPLIER?
